OBI Pharma will hold 10 poster presentations at the AACR Annual Meeting 2026.
Taipei, Taiwan, April 16, 2026 - (JCN Newswire) - OBI Pharma, Inc. (TPEx:4174.TWO) announced today its participation in AACR 2026.
Through 10 poster presentations, it will showcase the transformative potential of the GlycOBI platform.
This data will be presented at the American Association for Cancer Research (AACR) Annual Meeting, which will be held in San Diego, California, from April 17 to 22, 2026.
Dr. Ya-Chi Chen, Chief Scientific Officer (CSO) of OBI Pharma, stated, "At OBI, we are working on the creation of superior ADCs. Our goal is not only to target tumors more effectively and precisely but also to reduce side effects and provide patients with life-changing treatment options."

Inquiry about this news
Contact Us Online




